Initial attempts to treat ischemic cardiomyopathy with administration of autologous c-kit+ CPCs have yielded promising results in both animals and humans, many unanswered questions remain regarding the use of these cells for cardiac repair, and many hurdles need to be overcome to establish the efficacy of this new therapy [61]. The gene discussed is KIT; the disease is ischemic cardiomyopathy.